Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
NLRP3 Inhibitor
NLRP3-IN-58 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 3.85 μM. At a concentration of 10 μM, it effectively reduces IL-1β release by 33%. This compound is valuable for research applications focused on inflammatory pathways and the modulation of innate immune responses. -
NLRP3 Inhibitor
NLRP3-IN-56 is a potent inhibitor of the NLRP3 inflammasome, effectively suppressing IL-1β secretion in THP-1 cells with an IC50 of 9.7 nM. This compound serves as a valuable tool for investigating NLRP3-mediated inflammatory responses and associated pathologies. Its ability to modulate IL-1β levels makes it suitable for research into diseases characterized by NLRP3 activation. -
NLRP3 Inhibitor
NLRP3-IN-28 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an EC50 of 0.07 μM in the inhibition of Nigericin-induced pyroptosis. This compound effectively reduces inflammatory responses in vivo, making it a valuable tool for investigating NLRP3-related diseases and inflammatory pathways. Its application in research provides insights into therapeutic strategies targeting inflammasome activation and related inflammatory conditions. -
Inflammasome Inhibitor
3-Et-3TC is a potent inhibitor of the NLRP3 inflammasome, demonstrating its capacity to modulate inflammasome activation. This compound is valuable for investigating the underlying mechanisms of retinal degenerative diseases and other inflammatory conditions. Its structural modification from Lamivudine enhances its efficacy in biochemical research applications targeting inflammasome pathways. -
PD-L1 Inhibitor
INCB086550 is a potent oral small-molecule inhibitor of PD-L1, exhibiting IC50 values of 3.1, 4.9, and 1.9 nM for human, cynomolgus, and rat PD-L1, respectively. This compound promotes the dimerization of cell-surface PD-L1 and facilitates its entry into Golgi vesicles, leading to nuclear trafficking. INCB086550 is primarily used in cancer research, particularly in studies focusing on immune checkpoint regulation and tumor microenvironment modulation. -
PD-1/PD-L1 Interaction Inhibitor
PD-1/PD-L1-IN-9 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 3.8 nM. This compound enhances the antitumor activity of immune cells against tumor cells. Additionally, PD-1/PD-L1-IN-9 demonstrates significant in vivo antitumor efficacy in the CT26 mouse model, making it a valuable tool for cancer immunotherapy research. -
PD-L1 Inhibitor
BMS-986189 is a macrocyclic peptide that functions as a highly potent PD-L1 inhibitor, demonstrating an IC50 of 1.03 nM in disrupting the PD-1/PD-L1 interaction. This compound is suitable for cancer research applications, particularly in studies involving human lung carcinoma cells such as L2987, making it valuable for exploring immune checkpoint mechanisms and developing novel therapeutic strategies. -
PD-1/PD-L1 Inhibitor
BMS-8 is a selective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 7.2 μM. It directly binds to PD-L1, promoting the formation of PD-L1 homodimers, thereby obstructing the engagement with PD-1. This compound is primarily utilized in cancer immunotherapy research, particularly in studies focused on the modulation of immune checkpoint pathways. -
PD-1/PD-L1 PPI Inhibitor
Evixapodlin is a potent inhibitor of the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 of 0.213 nM. This compound demonstrates significant anticancer and antiviral activities, making it a valuable tool for research in immunotherapy and viral pathogenesis. Evixapodlin is particularly useful for studying the modulation of immune responses in tumor environments and understanding the interplay between immune checkpoints and viral infections. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-14 is a bifunctional inhibitor specifically targeting the PD-1/PD-L1 interaction, exhibiting an IC50 of 27.8 nM. This compound effectively disrupts PD-1/PD-L1 binding while promoting the dimerization, internalization, and degradation of PD-L1. Its unique mechanism of action supports research in immunotherapy and cancer treatment, making it a valuable tool for studies involving immune modulation and T-cell activation. -
PD-L1 Inhibitor
PD-L1-IN-3 is a PD-L1 inhibitor that effectively targets the PD-1/PD-L1 interaction. With an IC50 value of 4.97 nM for inhibiting PD-L1 and an EC50 value of 2.70 μM for Jurkat T cell activation, this compound disrupts PD-1 signaling by binding to the PD-L1 dimer. PD-L1-IN-3 is particularly valuable for research applications in lung cancer and melanoma, facilitating the study of immune checkpoint mechanisms in these diseases. -
PD-1/PD-L1 Inhibitor
MAX-10181 is a selective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 0.018 μM. This compound is instrumental in cancer research, facilitating the exploration of immune checkpoint blockade mechanisms and potential therapeutic applications in oncology and related diseases. Researchers can utilize MAX-10181 to study the modulation of immune responses in various tumor models. -
PD-1/PD-L1 Inhibitor
ARB-272572 is a potent small molecule inhibitor targeting the PD-L1 pathway, exhibiting an IC50 value of 400 pM. This compound enhances antitumor immunity and shows promise in the treatment of chronic viral infections. ARB-272572 is valuable for research applications focused on cancer immunotherapy and viral infection studies. -
PD-1/PD-L1 Inhibitor
N-deacetylated BMS-202 is a potent inhibitor of the PD-1/PD-L1 interaction. This compound plays a significant role in cancer immunotherapy by blocking the immune checkpoint pathway, thereby enhancing T-cell responses against tumor cells. Its application in research encompasses the investigation of tumor microenvironments and the evaluation of immune evasion mechanisms in various cancer types. -
PD-L1/PD-1 Inhibitor
BMS-1001 hydrochloride is an orally active inhibitor of the PD-L1/PD-1 immune checkpoint pathway. It demonstrates low cytotoxicity across various cell lines, making it suitable for research applications. The compound has an IC50 value of 2.25 nM in homogeneous time-resolved fluorescence (HTRF) binding assays, indicating potent inhibition of PD-1 interactions. BMS-1001 is useful for studies focused on cancer immunotherapy and the modulation of immune responses. -
PD-1/PD-L1 Inhibitor
ASC-69 is a potent inhibitor of the PD-1/PD-L1 pathway, which plays a critical role in immune evasion by tumors. This small-molecule compound demonstrates strong biological activity in inhibiting the interaction between PD-1 and PD-L1, thereby enhancing T-cell responses against cancer cells. ASC-69 is relevant for research applications focused on cancer immunotherapy and the modulation of immune checkpoint mechanisms. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-33 is a potent inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 of 6.3 nM. This compound enhances T-cell proliferation, activation, and infiltration into tumor microenvironments, thereby exerting immunomodulatory and anticancer effects. PD-1/PD-L1-IN-33 is applicable in research focused on cancer immunotherapy and the modulation of immune responses. -
PD-L1 Inhibitor
BMS-986238 is an orally active macrocyclic peptide that functions as a PD-L1 inhibitor. This compound exhibits significant anti-tumor activity by blocking the PD-1/PD-L1 interaction, enhancing immune responses against cancer cells. BMS-986238 is utilized in research applications focusing on solid tumors and lymphomas, providing insights into immune checkpoint modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-23 is a potent, orally active inhibitor of the PD-1/PD-L1 interaction. As an ester proagent of L7, a benzo[c][1,2,5]oxadiazole derivative, it has been evaluated for its ability to inhibit PD-L1. This compound demonstrates significant antitumor effects in various tumor models, including syngeneic and PD-L1 humanized mice, making it a valuable tool for cancer research and the development of immune checkpoint therapies. -
PD-L1 Inhibitor
PD-L1-IN-2 is an inhibitor of the programmed death-ligand 1 (PD-L1) pathway, functioning as a potential immunotherapeutic agent against tumors. This Naamidine J derivative demonstrates significant antitumor activity by downregulating PD-L1 expression, thereby enhancing T-cell infiltration and activity within tumors. PD-L1-IN-2 is applicable in preclinical research focused on colorectal cancer and other malignancies where PD-L1 plays a critical role in immune evasion. -
PD-1/PD-L1 Interaction Inhibitor
BMSpep-57 is a competitive macrocyclic peptide inhibitor targeting the PD-1/PD-L1 interaction, exhibiting an IC50 of 7.68 nM. It demonstrates strong binding affinity to PD-L1, with Kd values of 19 nM in Microscale Thermophoresis (MST) and 19.88 nM in Surface Plasmon Resonance (SPR) assays. By disrupting this interaction, BMSpep-57 enhances T cell function, leading to increased IL-2 production in peripheral blood mononuclear cells (PBMCs). This compound is valuable for research applications related to immunotherapy and T cell activation. -
PD-1/PD-L1 Inhibitor
Kaempferol-7-O-rhamnoside is a potent inhibitor of the PD-1/PD-L1 pathway and an agonist of the farnesoid X receptor (FXR). It exhibits cardioprotective properties by targeting the AMPKα1 signaling pathway, significantly enhancing mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Additionally, Kaempferol-7-O-rhamnoside effectively reverses acetaminophen-induced reductions in glutathione levels and mitigates reactive oxygen species production in L02 cells. This compound demonstrates potential applications in research related to heart failure and oxidative stress. -
PD-1 Inhibitor
PD-1-IN-24 is a potent inhibitor of the programmed cell death protein 1 (PD-1) pathway, demonstrating robust oral bioavailability. This compound effectively modulates immune responses by blocking PD-1 interaction with its ligands, which is crucial for enhancing anti-tumor immunity. PD-1-IN-24 is utilized in research to investigate immune regulation and develop cancer immunotherapies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-29 is a potent inhibitor of the PD-1/PD-L1 pathway, exhibiting an IC50 value of 6.1 nM. This compound effectively binds to PD-L1 to disrupt PD-1/PD-L1 interactions, facilitating PD-L1 dimerization and subsequent internalization, while enhancing its localization to the endoplasmic reticulum. PD-1/PD-L1-IN-29 demonstrates significant anticancer activity, making it a valuable tool for research in immuno-oncology and therapeutic applications targeting immune checkpoint pathways. -
PD-1/PD-L1 Inhibitor
BMS-37 is a potent PD-1/PD-L1 immune checkpoint inhibitor, demonstrating an IC50 ranging from 18 to 200 nM against the PD-L1/PD-1 complex. This compound exhibits significant toxicity toward modified Jurkat T cells, with an EC50 between 3 and 6 µM. BMS-37 is valuable for investigating PD-L1-mediated T-cell exhaustion and serves as a PD-L1 ligand in the synthesis of PROTAC molecules for targeted protein degradation studies. -
PD-1/PD-L1 Interaction Inhibitor
BMS-200 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 80 nM. This compound effectively disrupts the binding of PD-L1 to PD-1, which is critical in regulating immune responses. BMS-200 is valuable for research in cancer immunotherapy, particularly in elucidating mechanisms of immune checkpoint modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-NP19 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 12.5 nM. This compound is designed to enhance immune responses within the tumor microenvironment, potentially leading to significant antitumor activity. It is a valuable tool for researchers investigating immunotherapy and the modulation of immune checkpoints in cancer therapy. -
Inhibitor of PD-1/PD-L1 Protein-Protein Interaction
LH1307 is a C2-symmetric inhibitor of the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 value of 3.0 μM. This compound serves as a valuable tool for cancer research, enabling the exploration of immunotherapeutic strategies targeting the PD-1/PD-L1 axis. Its application can facilitate studies on immune evasion mechanisms in tumors and the development of novel cancer therapies. -
PD-1/PD-L1 Interaction Inhibitor
PD-1/PD-L1-IN-13 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 10.2 nM. This compound effectively promotes CD8+ T cell activation, enhancing anti-tumor immunity. Its application in preclinical models, such as the Hepa1-6 syngeneic mouse model, demonstrates its potential to delay tumor growth, making it valuable for research in immunotherapy and cancer biology. -
hPD-1/hPD-L1 Interaction Inhibitor
Human PD-L1 inhibitor V is a peptide that specifically targets the interaction between human PD-1 and PD-L1, exhibiting a binding affinity characterized by a Kd value of 3.32 μM. This inhibitor is valuable for research applications focused on immune checkpoint modulation and cancer immunotherapy, as it effectively disrupts the PD-1/PD-L1 signaling pathway, which is critical in the regulation of immune responses. -
PD-L1 Inhibitor
Human PD-L1 Inhibitor IV is a competitive inhibitor of the human PD-1 protein, exhibiting a Kd value of 1.38 μM. This polypeptide effectively disrupts the interaction between human PD-1 and PD-L1, facilitating research into immune checkpoint pathways. It is applicable for studies focused on cancer immunotherapy and the modulation of immune responses. -
PD-1/PD-L1 Inhibitor
IMMH-010 maleate is a prodrug that functions as a PD-L1 inhibitor, demonstrating significant potential for antitumor activity in neurological disorders and advanced malignant solid tumors. Upon oral administration, IMMH-010 maleate is swiftly converted to its active form, YPD-29B. This compound is designed to facilitate research in the area of PD-L1 inhibition and its therapeutic implications. -
PD-1 Inhibitor
PD1-PDL1-IN 1 is a potent inhibitor of programmed cell death 1 (PD-1), a critical checkpoint in immune regulation. This compound serves as an immune modulator, facilitating enhanced T-cell activation and proliferation. PD1-PDL1-IN 1 is valuable for research applications focused on cancer immunotherapy and elucidating immune response mechanisms. -
PD-1/PD-L1 Inhibitor
Human PD-L1 inhibitor II is a potent inhibitor of the PD-1/PD-L1 interaction, playing a crucial role in immune checkpoint regulation. This compound exhibits significant anti-cancer activity by enhancing T-cell responses against tumor cells. It is primarily used in research applications focused on cancer immunotherapy and understanding the mechanisms of immune evasion. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-36 is an inhibitor of the PD-1/PD-L1 complex, exhibiting an IC50 of 15 nM. This compound plays a crucial role in cancer immunotherapy research by blocking the interaction between PD-1 and PD-L1, which is instrumental in tumor immune evasion. Its application in studies may enhance understanding of immune checkpoint mechanisms and the development of novel therapeutic strategies in oncology. -
PD-1/PD-L1Inhibitor
SCL-1 is an orally active inhibitor of the PD-1/PD-L1 pathway, effectively blocking the interaction between PD-1 and PD-L1. This compound enhances the proliferation of T cells, B cells, and natural killer cells, contributing to robust antitumor activity. SCL-1 mediates tumor growth inhibition through the induction of effector T cells within the tumor environment and by upregulating long non-coding RNAs that act as neoantigens, facilitating cytotoxic T lymphocyte activation. This reagent is valuable for cancer research, particularly in studies focused on triple-negative breast cancer. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN 5 is a potent inhibitor of the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of ≤100 nM. This compound is valuable for studies investigating immune checkpoint inhibition and its role in enhancing anti-tumor immunity. Researchers can utilize this reagent in various applications related to cancer immunotherapy and the modulation of immune responses. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN 5 TFA is a potent inhibitor of the PD-1/PD-L1 protein-protein interaction, with an IC50 of ≤100 nM. This compound is beneficial for research applications focused on immune checkpoint modulation, particularly in the context of cancer immunotherapy. By blocking the PD-1/PD-L1 pathway, it aids in the investigation of T-cell activation and tumor immune evasion mechanisms. -
PD-1/PD-L1 Inhibitor
LLW-018 is a potent inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 value of 2.61 nM. This compound effectively disrupts the PD-1/PD-L1 pathway, showing an IC50 of 0.88 μM in cell-based assays. LLW-018 holds significant potential for applications in immunotherapy research, particularly in the development of cancer treatments that target immune checkpoint pathways. -
PD-1/PD-L1 inhibitor
PD-1/PD-L1-IN 6 is a potent inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 value of 132.8 nM. This compound exhibits significant immunoregulatory activity, notably enhancing interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, while exhibiting minimal toxicity. Additionally, PD-1/PD-L1-IN 6 is effective in restoring immune responses in T cell-tumor co-culture models, making it a valuable reagent for immunotherapy research and studies related to cancer immunology. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-32 is a potent inhibitor of the PD-1/PD-L1 pathway, exhibiting an IC50 of 2.4 nM. This compound demonstrates significant anticancer activity by effectively inhibiting tumor growth in a humanized mouse model expressing PD-L1. Importantly, PD-1/PD-L1-IN-32 exhibits limited toxicity on normal mouse tissues, making it a valuable tool for cancer research and therapeutic applications targeting immune checkpoint pathways. -
PD-L1 Inhibitor
BMS-1233 is a potent inhibitor of programmed cell death-ligand 1 (PD-L1) with an IC50 of 14.5 nM. This compound promotes cytotoxicity in HepG2 cells within a Jurkat T cell and HepG2 co-culture model, demonstrating significant antitumor activity against melanoma in in vivo mouse models. BMS-1233 is suitable for research applications focused on cancer immunotherapy and the modulation of immune checkpoint pathways. -
PD-L1/NAMPT Inhibitor
PD-L1/Nampt-IN-1 is a dual inhibitor targeting PD-L1 and NAMPT (nicotinamide phosphoribosyltransferase) with IC50 values of 63 nM and 582 nM, respectively. This compound exhibits cross-species affinity with comparable KD values for human PD-L1 (52.6 nM) and mouse PD-L1 (49.1 nM). PD-L1/Nampt-IN-1 facilitates tumor growth inhibition by enhancing the tumor immune microenvironment, making it a valuable tool for research in melanoma studies. -
PD-1/PD-L1 Inhibitor
LP23 is a potent non-arylmethylamine inhibitor of the PD-1/PD-L1 axis, exhibiting an IC50 of 16.7 nM. It effectively restores immune cell function in HepG2 and Jurkat T cell assays and promotes cell death in HepG2 cancer cells. In vivo studies demonstrate its significant anti-tumor activity in the B16-F10 tumor model, achieving a tumor growth inhibition of 88.6% at a dose of 30 mg/kg. This compound serves as a valuable tool for cancer immunotherapy research and the investigation of immune checkpoint pathways. -
PD-L1 Inhibitor
PD-L1-IN-5 is a potent inhibitor of programmed death-ligand 1 (PD-L1), exhibiting an IC50 value of 785.6 nM. This compound demonstrates significant anti-tumor activity in vivo, making it a valuable tool for cancer research. PD-L1-IN-5 is utilized in studies focusing on immune checkpoint regulation and therapeutic strategies aimed at enhancing anti-tumor immunity. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-26 is a potent inhibitor of the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, exhibiting an IC50 of 0.0380 μM. This compound enhances the immune microenvironment by facilitating the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 is valuable for research applications focused on cancer immunotherapy and the modulation of immune responses in tumor biology. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-59 is a PD-1/PD-L1 inhibitor with an IC50 value of 183 nM. This compound is instrumental in the investigation of immune checkpoint regulation and has significant potential for research applications in triple-negative breast cancer (TNBC) therapies. By blocking the PD-1/PD-L1 interaction, it fosters immune response against tumor cells and facilitates the exploration of novel immunotherapeutic strategies. -
PD-L1 Inhibitor
PD-1/PD-L1-IN-60 is an inhibitor of PD-L1, a key checkpoint protein involved in immune evasion of tumors. This compound demonstrates significant anti-tumor activity in preclinical models, particularly within melanoma and lung cancer contexts where PD-L1 expression is elevated. PD-1/PD-L1-IN-60 is suitable for research applications focused on immunotherapy, tumor immune microenvironment studies, and the evaluation of therapeutic strategies targeting PD-L1. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-20 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of 5.29 nM. This compound effectively disrupts the PD-1/PD-L1 pathway, making it a valuable tool for research in oncology, infectious diseases, and autoimmune disorders. Its ability to modulate immune checkpoint proteins provides significant insights into therapeutic strategies for enhancing anti-tumor immunity. -
PD-L1/PD-1 Inhibitor
PD-L1/PD-1-IN-1 is a potent inhibitor of the PD-L1/PD-1 interaction, demonstrating an IC50 of less than 1 nM. This compound is significant for research in anti-tumor therapies, facilitating the study of immune checkpoint modulation and its effects on tumor growth. Its ability to effectively block PD-L1 signaling makes it a valuable tool for exploring therapeutic strategies in cancer immunotherapy.
